Vanguard Russell 2000 Growth ETF
What Are Accelerate Diagnostics’ Key Strengths?
In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.
A Look at Ionis Pharmaceuticals’ Nusinersen
Ionis Pharmaceuticals (IONS) has entered into a collaborative agreement with Biogen Idec (BIIB) for the development and commercialization of nusinersen.